Skip to search formSkip to main contentSkip to account menu

rituximab/yttrium Y 90 ibritumomab tiuxetan

Known as: IDEC-Y2B8/MOAB IDEC-C2B8 
National Institutes of Health

Related topics

Related topics

2 relations
rituximabyttrium-90-ibritumomab tiuxetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas
Monoclonal antibodies (MoAbs) for cancer have been the subject of intense clinical investigation for nearly 2 decades.[1… 
Review
2006
Review
2006
Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature.
We are reporting on a 14-year-old boy with a very early relapse of pre-B acute lymphoblastic leukemia (ALL) and anaplastic… 
2005
2005
Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience
PurposeThe aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative… 
Highly Cited
2004
Highly Cited
2004
Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab
Rituximab (Rituxan, IDEC-C2B8) has been shown to sensitize non-Hodgkin’s lymphoma (NHL) cell lines to chemotherapeutic drug… 
2001
2001
Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody
Mantle cell lymphoma (MCL) has a poor prognosis without cure; the median overall survival ranges only from 3 to 4 years… 
2001
2001
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.
The chimeric monoclonal anti-CD20 antibody has been widely used for the treatment of relapsed or refractory low-grade B-cell non… 
Highly Cited
1998
Highly Cited
1998
Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
SummaryIn this report we present a patient with B-cell chronic lymphocytic leukemia who developed an acute tumor lysis syndrome… 
Review
1998
Review
1998
Clinical status and optimal use of rituximab for B-cell lymphomas.
Rituximab (IDEC-C2B8 [Rituxan]) is a chimeric anti-CD20 monoclonal antibody (MoAb) that was recently approved by the FDA for the… 
Highly Cited
1998
Highly Cited
1998
Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody
Treatment with IDEC‐C2B8 (C2B8), the chimeric anti‐CD20 antibody, was shown in a phase I‐II study to be very effective for the… 
1998
1998
Non-Hodgkin's lymphoma trials in elderly look beyond CHOP.
Researchers in December launched a new randomized trial for elderly patients with intermediate-grade nonHodgkin 's lymphoma (NHL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)